Rahway, New Jersey, United States, November 20, 2026
Merck & Co., Inc. has announced positive results from its global Phase 3 TroFuse-015 clinical trial, evaluating sacituzumab tirumotecan (sac-TMT) in patients with locally advanced unresectable or metastatic gastroesophageal adenocarcinoma who had received two or more previous lines of systemic therapy. The investigational TROP2-directed antibody-drug conjugate (ADC) met the study’s primary endpoint of overall survival (OS), demonstrating a statistically significant and clinically meaningful improvement compared with treatment of physician’s choice. The results represent an important development for patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinomas, particularly those whose disease has progressed following multiple treatment regimens. According to Merck, TroFuse-015 is the first global Phase 3 study in this patient population to demonstrate an overall survival benefit with a TROP2-directed ADC. The company stated that the findings were generally consistent across patient subgroups, regardless of TROP2 expression status. However, the study did not meet its secondary endpoint of progression-free survival (PFS) assessed by blinded independent central review. Merck plans to present the detailed findings at an upcoming medical meeting and share the data with regulatory authorities.
TroFuse-015 Demonstrates Overall Survival Improvement
The randomized, open-label, multicenter TroFuse-015 trial evaluated sac-TMT against treatment of physician’s choice in patients with locally advanced unresectable or metastatic gastroesophageal adenocarcinoma who had experienced disease progression after at least two prior lines of systemic therapy. The study enrolled 473 patients and compared sac-TMT with one of four physician-selected treatment options: trifluridine-tipiracil, irinotecan, paclitaxel or docetaxel. At the final analysis, patients receiving sac-TMT demonstrated a statistically significant and clinically meaningful improvement in overall survival compared with those receiving the control treatments. The findings were generally consistent across subgroups, including patients with different levels of TROP2 expression. This is notable because TROP2 expression was not required for participation in the study. Nevertheless, sac-TMT did not achieve the secondary endpoint of progression-free survival as assessed by blinded independent central review. The objective response rate also nominally favored sac-TMT over treatment of physician’s choice, but this result was not formally tested under the study’s prespecified statistical analysis plan. Merck reported that the safety profile was consistent with previously reported studies of sac-TMT, with no new safety signals observed. The company has not yet released detailed median overall survival values or hazard ratios in the announcement, making the upcoming scientific presentation important for understanding the magnitude of the treatment benefit.
Sacituzumab Tirumotecan: An Investigational TROP2-Directed ADC
Sacituzumab tirumotecan (sac-TMT) is an investigational antibody-drug conjugate designed to target TROP2, a protein expressed at elevated levels in many types of cancer. The medicine combines a TROP2-directed antibody with a belotecan-derived topoisomerase I inhibitor payload, which is intended to deliver cancer-cell-killing activity to tumour cells. Its proprietary bifunctional linker is designed to support payload delivery while limiting payload loss during circulation in the body. The candidate was originally developed by Kelun-Biotech, with Merck holding exclusive rights to develop, manufacture and commercialise sac-TMT outside Greater China under a licensing and collaboration agreement. Through this partnership, Merck is advancing the drug candidate across several solid tumour types and treatment settings. The investigational therapy is being evaluated both as a standalone treatment and in combination with other cancer medicines. Its development programme is designed to explore potential applications in patients with significant unmet medical needs, including those with advanced disease who have limited treatment options.
Positive TroFuse Results Expand Merck’s Oncology Programme
TroFuse-015 represents the second positive Phase 3 readout from Merck’s broader TroFuse clinical development programme evaluating sac-TMT. The programme includes 18 ongoing global Phase 3 trials across multiple cancer types, including endometrial, bladder, breast, cervical, gastric, non-small cell lung and ovarian cancers. These studies are investigating the candidate in different stages of disease and treatment settings, both as monotherapy and in combination with immunotherapies. The programme also includes more than 15,000 patients worldwide. Merck is continuing to evaluate whether sac-TMT can provide clinically meaningful benefits across a wider range of solid tumours. The latest TroFuse-015 findings add to the company’s clinical evidence for the candidate, particularly in heavily pretreated gastroesophageal adenocarcinoma. The company intends to discuss the findings with regulatory authorities and present the detailed results to the scientific community. Although the overall survival result is encouraging, the failure to meet the secondary progression-free survival endpoint remains an important consideration when interpreting the trial. Sac-TMT remains investigational for this indication, and the TroFuse-015 announcement does not represent regulatory approval.
Source: Merck press release



